INBX Healthcare

Inhibrx Biosciences, Inc.

$81.08+12.36%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 1.2B USD
Enterprise value: 1.4B USD
Full-time employees: 109

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 3.82 vs a peer median of 0.63)higher risk: bigger price swings (beta 3.82 vs peers 0.63)

Ranks #1,155 of 1,157 healthcare companies (bottom 1%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.
Inhibrx Biosciences's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Inhibrx Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Inhibrx Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Revenue is falling. Revenue fell 100% in the 12 months to June 2026 vs the 12 months before.
Inhibrx Biosciences's revenue fell 100% in the 12 months to June 2026 vs the 12 months before.

StockQuotient Score

6/ 100

Oct 5 10 → Nov 4 6 (-4)

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-11.6%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-10.2%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-11.1%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield-4.4%

SEC filings · latest balance sheetOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

11/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 100.0%

Why

Weaker than most peers on:

▼ Revenue growth
▼ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth-0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Reported value33% base weight · Z-score -0.70Sector median: 0.0584 · MAD: 0.0840

Revenue growth-100.0%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -4.87Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

0/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-10386.5%

Yahoo Finance fallback · SEC operating income not reported in standard form · fiscal year to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score -71.87Sector median: 0.0706 · MAD: 0.1217

Return on assets-89.6%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -11.22Sector median: 0.0166 · MAD: 0.0537

Return on invested capitalUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-1773.6%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta3.82

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio5.07×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.79Sector median: 2.5860 · MAD: 1.3850

Debt / equityUnavailable

Shareholders' equity is negative, so debt/equity counts as among the highest in its peer group33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Inhibrx Biosciences

Is Inhibrx Biosciences getting weaker?: Its latest SEC filing (Aug 13, 2026) got weaker in some ways: 12-month revenue fell 100.0%. Its overall score is unchanged at 6/100 since Oct 28, 2026.
How is Inhibrx Biosciences valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.6% vs peers 1.5% (weaker than 100% of peers).
Is Inhibrx Biosciences growing?: More slowly than most of its peers. Growth scores 11/100 against 1,393 healthcare peers. Revenue growth -100.0% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -100.0% vs peers 6.1% (weaker than 100% of peers).
How profitable is Inhibrx Biosciences?: Less profitable than most of its peers. Profitability scores 0/100 against 1,393 healthcare peers. Operating margin -10386.5% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -10386.5% vs peers 7.1% (weaker than 100% of peers).
How risky is Inhibrx Biosciences?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.07× vs a peer median of 2.59× (stronger than 74% of peers).Current ratio 5.07× vs peers 2.59× (stronger than 74% of peers). Beta 3.82 vs a peer median of 0.63 (weaker than 100% of peers).Beta 3.82 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 13, 2026 · compared with the quarter ended Dec 31, 2025

Got weaker

12-month revenue fell 100.0%

Worth watching: Inhibrx Biosciences is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.3M USD	0 USD	turned negative
Net income (12 months)	−130.2M USD	−138.2M USD	+6.1%
Free cash flow (12 months)	−131.9M USD	−131.9M USD	−0.0%
Debt	175.0M USD	176.3M USD	+0.7%
Cash	161.7M USD	133.3M USD	−17.5%
Shares outstanding	14.7M	14.7M	+0.3%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2023	FY 2024	FY 2025	Change
Operating margin	-12178.9%	-165724.0%	-10386.5%	▲ >999 pts
Net margin	-13408.9%	843786.0%	-10773.5%	▼ >999 pts
Return on assets (ROA)	-78.4%	933.6%	-95.6%	▼ >999 pts
Return on equity (ROE)	-554.8%	1263.3%	-1752.2%	▼ >999 pts
Free cash flow margin	-10994.6%	-98503.0%	-9986.5%	▲ >999 pts
Current ratio	5.25×	3.94×	3.93×	▼ 0.2%
Debt to equity	4.76×	0.00×	12.58×	—
Interest coverage	-6.89×	-24.57×	-11.07×	▲ 55%

INBX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 3.82 vs a peer median of 0.63)higher risk: bigger price swings (beta 3.82 vs peers 0.63)

Ranks #1,155 of 1,157 healthcare companies (bottom 1%)

See how it ranks against its peers

Worth knowing

Negative shareholders' equity. Liabilities exceed assets on the balance sheet.

Inhibrx Biosciences's liabilities exceed its assets on the balance sheet. Large share buybacks can cause this in healthy companies, but so can accumulated losses; either way, debt-based ratios need care.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Inhibrx Biosciences looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Inhibrx Biosciences reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Revenue is falling. Revenue fell 100% in the 12 months to June 2026 vs the 12 months before.

Inhibrx Biosciences's revenue fell 100% in the 12 months to June 2026 vs the 12 months before.

Questions investors ask about Inhibrx Biosciences

Is Inhibrx Biosciences getting weaker?

Its latest SEC filing (Aug 13, 2026) got weaker in some ways: 12-month revenue fell 100.0%. Its overall score is unchanged at 6/100 since Oct 28, 2026.

How is Inhibrx Biosciences valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -11.6% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -11.6% vs peers 1.5% (weaker than 100% of peers).

Is Inhibrx Biosciences growing?

More slowly than most of its peers. Growth scores 11/100 against 1,393 healthcare peers. Revenue growth -100.0% vs a peer median of 6.1% (weaker than 100% of peers).Revenue growth -100.0% vs peers 6.1% (weaker than 100% of peers).

How profitable is Inhibrx Biosciences?

Less profitable than most of its peers. Profitability scores 0/100 against 1,393 healthcare peers. Operating margin -10386.5% vs a peer median of 7.1% (weaker than 100% of peers).Operating margin -10386.5% vs peers 7.1% (weaker than 100% of peers).

How risky is Inhibrx Biosciences?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 5.07× vs a peer median of 2.59× (stronger than 74% of peers).Current ratio 5.07× vs peers 2.59× (stronger than 74% of peers). Beta 3.82 vs a peer median of 0.63 (weaker than 100% of peers).Beta 3.82 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.3M USD

0 USD

turned negative

Net income (12 months)

−130.2M USD

−138.2M USD

+6.1%

Free cash flow (12 months)

−131.9M USD

−131.9M USD

−0.0%

Debt

175.0M USD

176.3M USD

+0.7%

Cash

161.7M USD

133.3M USD

−17.5%

Shares outstanding

14.7M

14.7M

+0.3%

Key ratios

FY 2023

FY 2024

FY 2025

Change

Operating margin

-12178.9%

-165724.0%

-10386.5%

▲ >999 pts

Net margin

-13408.9%

843786.0%

-10773.5%

▼ >999 pts

Return on assets (ROA)

-78.4%

933.6%

-95.6%

▼ >999 pts

Return on equity (ROE)

-554.8%

1263.3%

-1752.2%

▼ >999 pts

Free cash flow margin

-10994.6%

-98503.0%

-9986.5%

▲ >999 pts

Current ratio

5.25×

3.94×

3.93×

▼ 0.2%

Debt to equity

4.76×

0.00×

12.58×

—

Interest coverage

-6.89×

-24.57×

-11.07×

▲ 55%